Skip to main content

Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Oct. 18, 2023 -- For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published in the Oct. 19 issue of the New England Journal of Medicine.

Stephen J. Freedland, M.D., from the Cedars-Sinai Medical Center in Los Angeles, and colleagues enrolled patients with prostate cancer with high-risk biochemical recurrence with a prostate-specific antigen doubling time of nine months or less. Patients were randomly assigned to receive enzalutamide daily plus leuprolide every 12 weeks, placebo plus leuprolide, or enzalutamide monotherapy (355, 358, and 355 patients, respectively).

The researchers found that metastasis-free survival was 87.3, 71.4, and 80.0 percent in the combination group, leuprolide-alone group, and monotherapy group, respectively. Enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival (hazard ratio for metastasis or death, 0.42); enzalutamide monotherapy was also superior to leuprolide alone (hazard ratio for metastasis or death, 0.63). There were no new safety signals noted; quality-of-life measures did not differ substantially between the groups.

"The data from this trial confirm findings in previous phase 3 trials, in which patients treated with the androgen-receptor inhibitor enzalutamide and androgen-deprivation therapy derived clinically meaningful benefit relative to androgen-deprivation therapy alone," the authors write.

The study was supported by Pfizer and Astellas Pharma, which manufacture enzalutamide.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

Black Patients More Likely to Experience MACE After ADT for Prostate Cancer

THURSDAY, June 20, 2024 -- Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy (ADT) for prostate cancer...

Higher County-Level Prostate Cancer Screening Tied to Better Outcomes

FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...

First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening

MONDAY, June 3, 2024 -- From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.